Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05051579 · ClinicalTrials.gov registry record · Phase 2

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

A Phase 2 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
272
Enrollment target

NCT05051579: Completed Phase 2 study, sponsored by Eli Lilly and Company.

NCT05051579 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 272 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (105% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05051579, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
272 participants
Enrollment target

Study Summary

The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.

Primary Outcome

Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

Interventions

  • DRUG Placebo
  • DRUG LY3502970

Trial Details

FieldValue
Enrollment Target 272 participants
Start Date 2021-09-29
Est. Completion 2022-11-22
Phase Phase 2
Eli Lilly and Company

1,341 total trials

What the finished NCT05051579 record still lists

NCT05051579 is an interventional study that assigns participants to a tested intervention. The registered 272 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (105% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT05051579 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05051579 about?

NCT05051579 is a clinical study titled "A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities". The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.

What is the current status of trial NCT05051579?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2021-09-29. Estimated completion is 2022-11-22.

What interventions are being tested in trial NCT05051579?

The interventions under investigation include: Placebo (DRUG), LY3502970 (DRUG).

Who is sponsoring clinical trial NCT05051579?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05051579's enrollment target sits among peer trials

272 204th of 2000 higher than 1,796 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02468024 · 272 participants · Phase 3

    JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

  • NCT05519449 · 272 participants · Phase 1

    Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

  • NCT06035939 · 272 participants · NA

    SMYLS Multi-site Trial

  • NCT06083051 · 272 participants · NA

    Differences in Postoperative Symptoms With Four Ureteral Stents

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05051579, the US trial registry maintained by the National Library of Medicine. NCT05051579 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.